Utilization of capecitabine-oxaliplatin (CAPOX) versus infusional 5-fluorouracil and oxaliplatin (FFOX) in the adjuvant treatment (AT) of resected high-risk colon cancer.

被引：0
|
作者：
Sha, Aaron
Abadi, Shirin
Gill, Sharlene
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14696
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14696
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
    Ducreux, Michel
    Bennouna, Jaafar
    Hebbar, Mohamed
    Ychou, Marc
    Lledo, Gerard
    Conroy, Thierry
    Adenis, Antoine
    Faroux, Roger
    Rebischung, Christine
    Bergougnoux, Loic
    Kockler, Leila
    Douillard, Jean-Yves
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (03) : 682 - 690
  • [22] PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN
    Chen, H. H.
    Chang, C. S.
    Chen, L. T.
    Chen, W. T.
    Hsu, T. C.
    Wang, J. Y.
    Wen, C. Y.
    VALUE IN HEALTH, 2009, 12 (07) : A278 - A278
  • [23] Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66 years or older
    Jones, Emily
    Duan, Zhigang
    Nguyen, Thinh T.
    Giordano, Sharon H.
    Zhao, Hui
    CANCER MEDICINE, 2023, 12 (03): : 2389 - 2406
  • [24] Erratum: Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
    A Sobrero
    G Frassineti
    A Falcone
    L Dogliotti
    R Rosso
    F Di Costanzo
    P Bruzzi
    British Journal of Cancer, 2005, 93 : 733 - 733
  • [25] Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study
    Osawa, Hiroshi
    Handa, Naoko
    Minakata, Kunihiko
    ONCOLOGY RESEARCH, 2015, 22 (5-6) : 325 - 331
  • [26] Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial
    Sinicrope, Frank A.
    Shi, Qian
    Catteau, Aurelie
    Poage, Graham M.
    Zemla, Tyler J.
    Mlecnik, Bernhard
    Benson, Al B.
    Gill, Sharlene
    Goldberg, Richard M.
    Kahlenberg, Morton S.
    Nair, Suresh G.
    Shields, Anthony F.
    Smyrk, Thomas C.
    Galon, Jerome
    Alberts, Steven R.
    JCO PRECISION ONCOLOGY, 2022, 6
  • [27] Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction
    Martinez-Lago, N.
    Vieito-Villar, M.
    Vidal-Insua, Y.
    Padin-Iruegas, M. E.
    Vazquez-Rivera, F.
    Candamio-Folgar, S.
    Lopez-Lopez, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (11): : 856 - 861
  • [28] CAPECITABINE PLUS OXALIPLATIN (CAPOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN STAGE III COLON CANCER: A COST-MINIMIZATION ANALYSIS BASED ON REAL WORLD COSTS IN THE NETHERLANDS
    van Gils, C. W. M.
    de Groot, S.
    Redekop, W. K.
    Uyl-De Groot, C. A.
    VALUE IN HEALTH, 2011, 14 (07) : A453 - A453
  • [29] Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction
    N. Martínez-Lago
    M. Vieito-Villar
    Y. Vidal-Insua
    M. E. Padin-Iruegas
    F. Vazquez-Rivera
    S. Candamio-Folgar
    R. Lopez-Lopez
    Clinical and Translational Oncology, 2015, 17 : 856 - 861
  • [30] COMPARATIVE EFFECTIVENESS OF ORAL 5-FLUOROURACIL MONOTHERAPY AS ADJUVANT CHEMOTHERAPY FOR HIGH-RISK STAGE-II COLON CANCER.
    Yoon, Byung Jun
    Cho, Jung Rae
    Oh, Heung-Kwon
    GASTROENTEROLOGY, 2019, 156 (06) : S1497 - S1497
12345